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Abstract
Protein O-mannosylation is a post-translational modification essential for correct develop-
ment of mammals. In humans, deficient O-mannosylation results in severe congenital mus-
cular dystrophies often associated with impaired brain and eye development. Although
various O-mannosylated proteins have been identified in the recent years, the distribution
of O-mannosyl glycans in the mammalian brain and target proteins are still not well defined.
In the present study, rabbit monoclonal antibodies directed against the O-mannosylated
peptide YAT(α1-Man)AV were generated. Detailed characterization of clone RKU-1-3-5
revealed that this monoclonal antibody recognizes O-linked mannose also in different pep-
tide and protein contexts. Using this tool, we observed that mono-O-mannosyl glycans
occur ubiquitously throughout the murine brain but are especially enriched at inhibitory
GABAergic neurons and at the perineural nets. Using a mass spectrometry-based
approach, we further identified glycoproteins from the murine brain that bear single O-man-
nose residues. Among the candidates identified are members of the cadherin and plexin
superfamilies and the perineural net protein neurocan. In addition, we identified neurexin 3,
a cell adhesion protein involved in synaptic plasticity, and inter-alpha-trypsin inhibitor 5, a
protease inhibitor important in stabilizing the extracellular matrix, as new O-mannosylated
glycoproteins.
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Introduction
Protein O-mannosylation is an essential post-translational modification in fungi, animals and
humans (reviewed in [1, 2]). In mammals, a heteromeric complex of protein O-mannosyltrans-
ferase 1 and 2 (POMT1, POMT2) transfers the initial mannose to serine and threonine residues
of target proteins entering the endoplasmic reticulum (ER) using dolichol phosphate-activated
mannose as carbohydrate donor [3]. The furthermodification of the protein-linkedmannose
includes its elongation in the Golgi apparatus. Linear core m1 (GlcNAcß1,2Man) and branched
core m2 glycans ((GlcNAcß1,6)GlcNAcß1,2Man) are initiated by protein O-mannose β1,2-N-
acetylglucosaminyltransferase 1 (POMGnT1) and β1,6-N-acetylglucosaminyltransferase
(GnT-Vb/GnT-IX). These structures are further elongated by ß1,4-linked galactose and neura-
minic acid derivatives [4, 5]. In addition, the synthesis of core m3 glycans is initiated by
β1,4-N-acetylglucosaminyltransferase 2 (POMGnT2) in the ER. Core m3 glycans
(GlcNAcß1,4Man) are elongated by β1,3-linkedN-acetylgalactosamineand the addition of a
phosphate group to the 6-position of the initial mannose. In the Golgi, the phosphate group is
furthermodified by repetitive disaccharide units of [-3-xylose-α1,3-glucuronic acid-β1-]. This
so calledmatriglycan is so far only found on α-dystroglycan (α-DG), which is the best investi-
gated O-mannosylated protein today (reviewed in [6]).
In mice, absence of POMT1 or POMT2 results in embryonic lethality [7, 8]. Defective pro-
tein O-mannosylation in humans leads to a group of congenital muscular dystrophies referred
to as α-dystroglycanopathies. Hallmarks are muscular dystrophy and severe malformations of
the eye and brain [9, 10]. α-Dystroglycanopathies vary in severity, with the most fatal ones
being theWalker-Warburg syndrome (WWS) and the muscle-eye-brain disease (MEB). In the
brain, symptoms comprise neuronal over-migration leading to cobblestone (type II) lissence-
phaly and accompanying hydrocephalus in the cerebral cortex region, as well as drastic brain
stem, pons and cerebellar hypoplasia [11–13]. Most of the clinical manifestations can be
explained by a structurally impaired pial basement membrane, which allows for over-migra-
tion, subsequent perturbedplacement of neurons past the glia limitans, and lamination defects
[14, 15]. Causative for these defects is the insufficient glycosylation of α-DG, leading to
impaired binding to extracellularmatrix (ECM) proteins such as laminin, agrin or neurexin
(reviewed in [6]). Notably, this binding requires the functionalmatriglycan, which can be
stained for by the IIH6 antibody [16, 17]. It was suggested that the length of the matriglycan
directly correlates with potential binding events and therefore a more tightly packed ECM [18].
Disease-relevantmouse models verified that O-mannosylation is of major importance during
embryonic brain development, especially for the structural build-up of the pial basement mem-
brane [19, 20].
Early structural analysis of O-glycans in rabbit brain indicated 30% of all O-linked glycans
to be of the O-mannosyl type [21, 22]. Also more recent global O-glycomics approaches
revealed significant levels of O-mannosyl glycans in the mouse brain [23]. But, α-DG bears
only a minor amount of the total O-mannosyl glycans in the mammalian brain [24]. In the
past years, the identification of furtherO-mannosylated proteins by high-throughput mass
spectrometry (MS) -basedmethods was limited by technical and methodical constraints, such
as the lack of suitable strategies for the enrichment of O-mannosyl glycoproteins or -peptides,
handling the sample complexity of multiple and heterogeneously glycosylated peptides, or the
instability of glycan modifications in MS fragmentation techniques. Thus, only a limited num-
ber of O-mannosylated proteins were identified frommouse or bovine brain, such as the cell
surface glycoprotein CD24, the protein tyrosine phosphatase receptor-type z polypeptide 1
(RPTPz, encoded by the PTPRZ1 gene), the cell adhesion protein neurofascin, and the ECM
proteins versican and neurocan [25–30]. Recent advances in enrichment strategies of O-
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mannosyl glycopeptides followed by MS-based sequencing have paved the way for the identifi-
cation of new O-mannosylated glycoproteins. Vester-Christensen and coworkers described the
human O-mannose glycoproteome from glyco-engineeredbreast cancer cells where early gly-
can elongation steps in the Golgi apparatus were omitted to reduce the glycan complexity of
the sample [31]. In combination with lectin weak affinity chromatography (LWAC) and
advancedMS/MS techniques this so-called “SimpleCell” strategy resulted in the identification
of cadherins and plexins as major targets of O-mannosylation. In order to discover O-manno-
sylated proteins directly from native tissues, we recently applied glycosidase treatment to gen-
erate glycopeptides bearing predominantly O-linkedmannoses, and extracted those from
complex peptidemixtures by the mannose-binding lectin concanavalin A (ConA). O-manno-
sylated peptides were then identified by combining the enzymatic specificity of α-mannosidase
with quantitative liquid chromatography (LC)-MS/MS analyses after dimethyl labeling using
stable isotopes [32]. This approach identified T- and E-cadherin from rabbit skeletal muscle
and human embryonic kidney cells (HEK293), respectively, and revealed that in contrast to
other known O-mannosylated proteins, predominantly single mannose residues are attached
to these cell adhesionmolecules [8, 32].
Despite the recent advances, the knowledge about the occurrence of O-mannosyl glycans in
the mammalian brain is still limited. Here we took advantage of a new rabbit monoclonal anti-
body for detection of unsubstituted O-mannosyl glycans and characterized their distribution in
the adult murine brain. Furthermore, using the recently establishedMS-based approaches, we
identified new proteins from this organ which contain single O-linkedmannose residues.
Materials and Methods
Animals
Mice used for this study were kept by the animal welfare officers of the University of Heidel-
berg. POMT2f/f;Emx1-Cre+ and POMT2f/f;Emx1-Cre- mice were raised and sustained by the Institu-
tional Animal Care and Use Committee of SUNY Upstate Medical University according to the
guidelines of the National Institute of Health. Adult C57BL/6 (Black6) mice in between 8 and
24 weeks of age were sacrificedusing isoflurane and freshly extracted brains were immediately
processed for cryo-embedding.GADCre mice were kindly provided by Dr. Hannah Monyer
and Dr. Anne Herb. All experiments were in agreement to the directives and permits of the
University of Heidelberg and the Animal Protection Law.
Monoclonal antibody production and hybridoma culture
Rabbit monoclonal antibodies were produced in contract with Epitomics Inc (Woerdern, Aus-
tria). The immunogen KLH-C-Ahx-YAT[α1-Man]AV was synthesized, consisting of the key-
hole limpet hemocyanin (KLH) as an immunostimulant, the O-mannosylated hexapeptide and
the linker amino acid aminocaproic acid (Ahx). Four rabbits were immunized with the immu-
nogen for five consecutive times and sera were evaluated using an established protocol from
Epitomics for differential enzyme-linked immunosorbent assay (ELISA) using O-mannosy-
lated or non-modifiedpeptides. Sera were further evaluated for their specificity using enriched
α-DG fractions from rabbit muscle as previously described [8]. One rabbit serumwas tested
positive, lymphocytes were extracted by splenectomy and fusedwith myeloma. 144 single
hybridomas were screened by differential ELISA. A total of 38 clones specifically reacted with
the mannosylated pentapeptide, and were further analyzed by Western blot using enriched α-
DG fractions. In addition, reactivity against the recombinant proteins Nfasc186, hDGdel2 and
hDG5was tested (see below). Seven clones were identified to be exclusively directed against the
mannosylated peptide. Another ten clones reacted with the O-mannosylated proteins as well.
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From these positive clones, RKU-1-3-5 was chosen for further propagation. Hybridoma cells
were cultivated in RPMI1640 medium (Invitrogen/Life Technologies, Darmstadt, Germany),
supplemented with Rabbit Hybridoma Supplement A (ab138912, Abcam, Cambridge, UK),
fetal bovine serum (HYCLSH30080.03, VWR, Darmstadt, Germany), 1x HAT (21060–017,
Invitrogen), 2 mMGlutaMAX-I (35050–061, Invitrogen) and 55 μM 2-mercaptoethanol
(21985–023, Invitrogen). Antibody production was conducted according to Epitomics estab-
lished protocols and suggestions. In brief, cells were adapted to serum-freemedium consisting
of IS MAB-CDmedium (IS MAB-CD 91104, Irvine Scientific, Santa Ana, USA), supplemented
with 4% (v/v) GlutaMAX (35050–061, Invitrogen) and 1x antibiotic-antimycotic (15240–062,
Invitrogen), transferred to the cell compartment of a CELLine CL1000 incubator flask (Integra,
Fernwald, Germany) and supplemented with 1 mg/ml BSA (A9578-50mL, Sigma-Aldrich,
Munich, Germany). After cultivation for a total of 22 to 25 days, cell supernatants were col-
lected,monoclonal IgG antibodies were enriched using Protein G columns and desalted with
desalting columns followingmanufacturer’s instructions (GE Healthcare/Amersham, Munich,
Germany and Epitomics).
Cryosectioning and immunofluorescence analyses
Extracted brains were immediately embedded in tissue freezingmedium (Jung) in embedding
bowls (16848B; Polysciences, Eppelheim, Germany) on dry ice. 12 μm sections were mounted
on Superfrost Plus carrier slides (H867.1; Carl Roth, Karlsruhe, Germany) and stored at—
20°C. Sectionswere thawed for 30 min prior to fixation with 2% (wt/vol) paraformaldehyde in
PBS for 20 min. After washing 3 times with 0.5x Tris-buffered saline (0.5x TBS), sections were
blocked with 5% (vol/vol) Chemiblocker (2170-S; Chemicon/Merck Chemicals, Darmstadt,
Germany) in 0.5x TBS containing 0.05% (vol/vol) Tween-20 (0.5x TBS/T) for 1 h. Primary
antibodies were applied overnight in 0.5x TBS/T containing 5% (vol/vol) Chemiblocker in a
humid chamber at 4°C. Secondaryantibodies were incubated for 1 h diluted in 0.5x TBS/T con-
taining 5% (vol/vol) Chemiblocker. Nuclei were counterstained with 0.3 μM DAPI for 3 min
and sections were mounted in AquaPolyMount (Polysciences). For a list of used antibodies
please refer to S1 Table (Santa Cruz, Heidelberg, Germany; R&D systems, Minneapolis, USA;
Vector Laboratories, Burlingame, USA).
If necessary, antibody solutions were pre-incubated with 150 μM and 190 μM of O-manno-
sylated YATAV or non-modifiedpeptide on a nutator for 24 h prior to application to the stain-
ing protocol above. Antibodies and peptides were diluted in 0.5x TBS/T containing 5%
Chemiblocker.
For co-localization of neurocan with the epitopes recognizedby the α-O-Man antibody, sec-
tions were detected in a sequential manner. After thawing, fixing and blocking the sections as
described above, the primary neurocan antibody was applied in 5% Chemiblocker in 0.5x TBS/
T for 1h. The secondaryα-sheepCy3 antibody was applied thereafter diluted in 0.5x TBS/T
containing 5% Chemiblocker for 1 h. Subsequently, sections were incubated with the primary
α-O-Man antibody diluted in 0.5x TBS/T containing 5% Chemiblocker overnight at 4°C in a
humid chamber and the staining protocol described above was further utilized. All other dou-
ble stainings were carried out using the standard staining protocol and applying both primary
and secondary antibodies together.
Detection of mouse antigens on mouse tissue was essentially performed as described in Bee-
dle et al. 2012 [33]. Briefly, sections were thawed and fixed as described above and incubated
with 0.1 M glycine/PBS for 10 min and 0.05% SDS/PBS for 30 min at 50°C. After blocking with
5% (vol/vol) goat serum (Jackson Immuno Research,West Grove, USA) in PBS for 1 h, endog-
enous IgG antibodies were blocked with 0.1 mg/ml PBS mouse F(ab)-fragment (Jackson
Mono-O-Mannosylation and Mammalian Brain
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ImmunoResearch) for 1 to 2 h and primary antibodies diluted in 5% goat serum in PBS were
applied overnight in a humid chamber. Nuclei were stained and sections were mounted as
described above.
For removal of N-linked glycans, murine brain cryosectionswere thawed, fixed with 4% (w/
v) Paraformaldehyde in PBS for 20 min at RT and washed 3 times in 0.5x TBS. Glycan trim-
ming was performed in the recommended buffer at 37°C for 3 h using 500 U of PNGase F
(P0704L, New England Biolabs (NEB), Frankfurt amMain, Germany). After 5 washing steps
with 0.5x TBS, antibody or lectin detectionwas continued as stated.
All immunostained images were acquired with a confocal Nikon 90i microscope. Pictures
were analyzed using Adobe Photoshop CS4, wherein tonal values, contrast and gradation
curveswere optimized in comparable manners.
Recombinant proteins
Recombinant proteins were produced and purified as described in Pacharra et al. 2012 for
recombinant NFASC186 and in Breloy et al. 2008 for recombinant hDGdel2 and hDG5 [27,
34].
Western blot analysis
Recombinant proteins (~ 0.4 μg each) were separated on 12% SDS-PA gels and transferred to
nitrocellulose, as described in Sambrook et al. 2001 [35]. Blots were incubated with rabbit α-
O-Man (1:25) or mouse α-pentaHis (Qiagen, Hilden, Germany; 1:2500) antibodies and the
respectiveHRP-conjugated secondary antibodies (Sigma-Aldrich; 1:5000). Detectionwas per-
formed by using ECL solutions (Amersham) and ImageQuant LAS500 (GE lifesciences).
Glycopeptide enrichment
Sample preparation was done as described [31] with minor modifications:Mouse brain of a
8–12 weeks old mouse (~0.4 g) was pulverized in liquid nitrogen and dissolved in 4 ml lysis
buffer (1% sodium deoxycholate (SDC), 10 mM tris(2-carboxyethyl)phosphine, 40 mM
2-chloroacetamide, 50 mM triethylammonium bicarbonate pH 8.5), heat inactivated at 90°C
for 15 min and sonified (output control 6, duty cycle 60%) for 30 min. After centrifugation
(1,000 × rcf for 10 min) the supernatant was incubated with TrypZean trypsin (1.6 mg, 1:250,
Sigma-Aldrich) dissolved in 160 μl 0.01% trifluoroacetic acid (TFA) at 37°C overnight (16 h).
Trypsin was heat inactivated (90°C, 30 min) and N-glycans were removed with PNGase F
(4 μl, 37°C, 6 h, NEB). The sample was acidifiedwith 1% TFA to precipitate SDC. After centri-
fugation (4000 × rcf for 5 min) peptides were desalted with two C18 Sep-Paks (500 mg,Waters,
Milford, USA) and dried by SpeedVac overnight. For ConA separation the peptides were dis-
solved in 1 ml freshly prepared ConA buffer (10 mMTris/HCl, pH 7.4, 150 mMNaCl, 1 mM
CaCl2, 1 mMMgCl2, 1 mMMnCl2, 1 mM ZnCl2, 0.5 M urea) and loaded on a preequilibrated
ConA lectin agarose column (3.5 m x 1 mm). The column was washed with 20 ml (~10 CVs)
ConA buffer (100 μL/min) and peptides were eluted with ConA buffer containing 0.5 M α-
D-Glucose (10 ml, 100 μL/min). The wash fractions (2 ml after the main flow-through passed)
and the elution fractions were desalted by a C18 Sep-Pak column (100 mg,Waters), dried by
SpeedVac and resuspended in a total volume of 30 μl of 0.1% TFA.
Liquid chromatography and mass spectrometry
Peptides were subjected to dimethyl labeling treatment as describedpreviously [32], or alterna-
tively directly analyzed by subsequent trapping (UltiMate 3000 nanoRSLC; 5 μm Acclaim
Mono-O-Mannosylation and Mammalian Brain
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PepMap100 300 μm × 5 mm, Thermo Scientific, Schwerte, Germany) at a flow rate of 30 μl/
min (1% acetonitrile (ACN), 1% formic acid (FA)). After 3 min peptides were separated on an
analytical column (2 μm Acclaim PepMap RSLC 75 μm × 25 cm, Thermo Scientific) using a
gradient of solution A (1% ACN, 5% DMSO, 0.1% FA) and B (90% ACN, 5% DMSO, 0.1%
FA): 3% to 40% B in 110 min; 40% to 90% B in 10 min.; flow rate: 300 nl/min. Full-scanmass
spectra (LTQ Orbitrap Elite MS (Thermo Scientific))were acquired in the positive ion mode at
30000 resolution, followed by higher-energy collisional dissociation (HCD) fragmentation of
the twenty most intense ions in the profile mode at 15000 resolution.
Data processing
The MS data were analyzed as described [32] with minor modifications: Analysis was done
with standard settings except noted otherwiseusing MaxQuant version 1.5.1.2 [36] and
Andromeda search engine [37]. The UniProt mouse database was used (downloaded 01/16/
2015, database entries: 83101). Carbamidomethylation of cysteine was set as a fixedmodifica-
tion. Methionine oxidation, asparagine/glutamine deamidation, protein N-terminus acetyla-
tion and serine/threoninehexosylation were set as variable modifications. For quantitation
light and medium dimethyl label were added for the protein N-terminus and lysine. A minimal
peptide length of 7 amino acids and a maximum of 2 miscleavages were allowed. The minimal
score and deltascore for modifiedpeptides were set to the default values 40 and 8, respectively.
The maximum peptide spectrummatch, proteins and site decoy fraction (FDR) were set to
0.01. ‘‘Re-quantify” and ‘‘Match between runs (2 min)” was activated. Bioinformatic data anal-
ysis was done with Perseus. In addition all the fragment spectra of modifiedpeptides were
hand annotated. Extracted ion chromatograms were done using the Qual browser software
(Thermo Scientific) with the calculated peptidemass and a tolerance of 10 ppm.
Results
RKU-1-3-5 rabbit monoclonal antibody detects mono-O-mannosyl
glycans in all regions of the mouse brain
We aimed to decipher the expression / distribution of protein O-mannosyl glycans in the
mouse brain. Therefore, rabbit monoclonal antibody directed against the peptide YAT
[α1-Man]AV, which does not react with the unglycosylated peptide YATAV, were established
as detailed in Materials and Methods. 38 selected hybridoma clones were further evaluated for
their ability to detect recombinant variants of human α-DG (hDG5 and hDGdel2) and human
neurofascin 186 purified from HEK293T cells. For these proteins distinct O-mannosylation
patterns have been demonstrated previously by mass spectrometry. On α-DG variant hDG5 no
O-mannosyl glycans have been identifiedwhereas on the hDGdel2 variant and on neurofascin
186 different types of O-mannosyl glycans, including unextendedmannose residues, have been
shown [27, 34]. In Western blots the monoclonal antibody RKU-1-3-5 (hereafter referred to as
α-O-Man) recognizedhuman neurofascin 186 and hDGdel2, but not the α-DG variant hDG5
(Fig 1A), further indicating its specificity. Glycopeptide array analysis demonstrated that the
α-O-Man antibody reacts with Thr-coupled mannose in various peptide environments
although to differing degrees (S1 Fig). Within the same peptides, elongated linear O-mannosyl
glycans of the structures GlcNAcß1,2Man and Galß1,4GlcNAcß1,2Man as well as clustered
mannoses and clustered GlcNAcß1,2Man glycans were not recognized (S1 Fig). Furthermore,
to examine the specificity of α-O-Man towards diverse glycan sequences, it was analyzed using
a neoglycolipid (NGL)-based oligosaccharidemicroarray of 492 oligosaccharide probes (S2
Fig). The repertoire of the probes encompasses a variety of mammalian type sequences,
Mono-O-Mannosylation and Mammalian Brain
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representative of N-glycans (high-mannose-type and neutral and sialylated complex-type);
peripheral regions of O-glycans; blood group antigen-related sequences (A, B, H, Lewisa,
Lewisb, Lewisx, and Lewisy) on linear or branched backbones and their sialylated and/or
sulphated analogues; linear and branched poly-N-acetyllactosamine sequences; gangliosides;
oligosaccharide fragments of glycosaminoglycans and polysialic acid. The array also included
microbial and plant-derived homo-oligomers of glucose and of other monosaccharides.
Screening analysis using the NGL-basedmicroarray revealed binding of α-O-Man to both ser-
ine and threonine-linkedmannose with a preference to the former (S2 Fig). Under the assay
conditions, some cross reactivities were found of a number of mannose-terminating sequences,
e.g. short α-linkedmannose sequences, small oligomannose N-glycans (found in relatively
large amounts in invertebrates and plants but not in mammals) and β1-4-linked oligomannose
glycans (derived from plant polysaccharides and absent in mammals). To further investigate
the binding of α-O-Man to oligomannose/high-mannose type N-glycans, the antibody was
tested at different dilutions (S2 Table; S3 Fig), and the results suggest that at higher dilutions
the antibody is more specific to α1-O-mannose amino acid probes. When coupled to a peptide
backbone, no cross reactivities towards the core N-glycan structureMan3GlcNAc2 was
detected (S4 Fig).
For further evaluation of clone RKU-1-3-5, we performed immunostaining of brain cross
sections of adult wild-typemice. The α-O-Man antibody showed significant reactivity through-
out the entire brain (Fig 2A). Immunoreactivity was completely lost when the α-O-Man anti-
body was pre-adsorbedwith the O-mannosylated peptide (YAT[α1-Man]AV) whilst the
unmodifiedpeptide (YATAV) did not alter the staining intensity or pattern (S5A Fig). In addi-
tion, we took advantage of transgenic mice with a brain-specific knockout of POMT2 to further
investigate the specificity of the α-O-Man monoclonal antibody. In POMT2f/f;Emx1-Cre+mice
O-mannosylation is abrogated in the neurons of the neocortex and the hippocampus, and in
the glial cells of the pallium, whereas the cerebellum is not affected [20]. In agreement, staining
Fig 1. Specificity of the α-O-Man monoclonal antibody. A) Western blot analysis of recombinant His-tagged
proteins [27, 34]. The α-O-Man antibody only detected O-mannosylated proteins (hNFASC186 and hDGdel2), whereas
non-modified hDG5 was not recognized. B) Immunofluorescent staining with α-O-Man was drastically reduced in the
cerebral cortex of POMT2f/f;Emx1-Cre+ mice (upper panel). Cerebral cortex layers are indicated on the left (I to VI). In
contrast, staining of the Purkinje cell layer was comparable in the cerebellum, where cre is not expressed (lower
panels). C) Cryosections of wild-type mouse brain were treated with PNGase F to remove all types of N-glycans.
Efficient elimination is demonstrated by Wisteria floribunda agglutinin (WFA) staining, a marker of perineural nets [38]
that is reactive to complex type N-glycans [39, 40]. No reduction in α-O-Man antibody signal upon N-glycan removal
was observed. B,C) Nuclei were counterstained with DAPI, sections were cut sagittally. Scale bars = 50 μm.
doi:10.1371/journal.pone.0166119.g001
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Fig 2. Mono-O-mannosyl glycans localize to distinct cell types throughout the murine brain. Sagittal section of WT murine
brain counterstained with DAPI for nuclei labeling. A) Broad staining was achieved as shown in the overview (scale bar = 100 μm) and
at higher magnifications in the cerebral cortex (1), the cerebellum (2), and the hippocampus (3). In more detail, staining in the
cerebellum included single cells of the molecular layer, cells of the granular cell layer and cells of the Purkinje cell layer (indicated by
asterisks). In the hippocampus, cells of the cornu ammonis region were labeled including their neuronal projections as indicated by
arrowheads (picture 3 shows cells of the CA2 field). Individual cells of regions II to V of the cerebral cortex were stained by the α-
O-Man antibody. Co-localization of mono-O-mannosyl glycans with neuronal cell marker (NeuN/Fox3) in the hippocampus (B) or with
Purkinje cell marker (Calbindin) in the cerebellum (C) showing single channel signal and merged channels. NeuN-labeled
hippocampal neurons of the cornu ammonis 2 (CA2) region were stained by the α-O-Man antibody. Purkinje cell localization of mono-
O-mannosyl glycans was demonstrated by co-localization with Calbindin. Scale bar = 50 μm.
doi:10.1371/journal.pone.0166119.g002
Mono-O-Mannosylation and Mammalian Brain
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of the Purkinje cell layer of the cerebellum (see below) of POMT2f/f;Emx1-Cre+ and control mice
showed similar α-O-Man staining patterns (Fig 1B, lower panel). As shown in Fig 1B (upper
panel), immunoreactivity of the α-O-Man antibody was almost absent in the cerebral cortex of
POMT2f/f;Emx1-Cre+mice as compared to wild-type littermates. Removal of N-glycans by
PNGase F did not interfere with α-O-Man antibody binding (Fig 1C), substantiating the speci-
ficity of the immunostaining on cryosections. In addition, whenO-mannosyl glycan biosynthe-
sis was blocked by a POMT-specific inhibitor [8] in Madin-Darby canine kidney epithelial cells
α-O-Man staining was omitted (S5B Fig), further demonstrating that the new α-O-Man mono-
clonal antibody is well suited for detection of mono-O-mannosyl glycans in situ.
Mono-O-mannosyl glycans are particularly concentrated in inhibitory
GABAergic neurons
α-O-Man immunostaining revealedmono-O-mannosyl glycans in all regions of the adult
wild-typemouse brain (Fig 2A). Concentrated staining of neuronal cell bodies of the layers II
to VI of the cerebral cortex (Fig 2A, panel 1), and single cells in the molecular cell layer, as well
as the Purkinje cell and the granular cell layers of the cerebellum (Fig 2A, panel 2) was
observed. Further, staining of pyramidal cells of the cornu ammonis (CA), including the pro-
jecting neurons, and of granular cells of the dentate gyrus (DG) in the hippocampus was pro-
nounced (Fig 2A, panel 3). To better illustrate the staining profile in the hippocampus, α-
O-Man antibody staining was compared to that of the neuronal marker NeuN/Fox3 [41]. We
observedoverlapping cell labeling of the CA field, but also identified additional cells in the
areas surrounding the CA region (Fig 2B). In the cerebellum,α-O-Man staining of Purkinje
cells was verified by Calbindin, a marker for Purkinje cells and their processes in cerebellar
nerve tracts [42]. As shown in Fig 2C, in addition to Purkinje cells (indicated by asterisks) sin-
gle cells from the molecular layer and, to some extent, granule cells were labeled by the α-
O-Man antibody.
Our data indicated that GABAergic neurons (e.g., Purkinje cells), are preferentially stained
by the α-O-Man antibody. To further verify this issue, we compared the pattern obtained by
the α-O-Man antibody to gephyrin, a knownmarker for inhibitory GABAergic neurons [43].
As shown in Fig 3A, the staining overlapped to a high extent in the hippocampus (upper pan-
els) and cerebellum (lower panels), although additional α-O-Man epitopes were detected for
example in the granular cell layer (see also inlay in lower panel 3). Moreover, in brains from
transgenic mice expressing the cre protein in GABAergic neurons [44] perfect co-localization
of α-O-Man immunoreactivity with cre-positve neurons was observed. (Fig 3B), further cor-
roborating the pronounced occurrence of mono-O-mannosyl glycans in GABAergic inhibitory
neurons. In contrast, no matching or overlapping staining patterns of α-O-Man and peanut
agglutinin (PNA), a marker for myelinated axons and white matter (Fig 3C), as well as the glial
cell marker glial fibrillary acidic protein (GFAP; Fig 3D) were observed.
Next, we compared staining patterns of α-O-Man with previously describedO-mannosyla-
tion target proteins. The most intensive studied glycoprotein carryingO-mannosyl glycans is
α-DG. Localization of α-DGwas assessed by the monoclonal antibody clone IIH6, which is
known to bind to a carbohydrate-moiety that mediates the interaction betweenα-DG and lam-
inin [16, 17]. Staining of sequential brain sections of wild-typemice showed comparable signals
as illustrated exemplarily for the cerebellum (Fig 4A and S5C Fig and data not shown). As
shown in Fig 4A, α-DGwas detected in Purkinje cell and granular cell layers. In addition,
prominent staining of vasculature was observed for IIH6 and laminin-reactive antibodies, but
not for α-O-Man suggesting that the α-O-Man-directed epitope is not accessible in these struc-
tures. Furthermore, Plexin B2, an O-mannosylated transmembrane receptor involved in axon
Mono-O-Mannosylation and Mammalian Brain
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guidance and cell migration [45], co-localizedwith the α-O-Man signal of the Purkinje cell
layer, but was absent in granular and molecular cell layers (Fig 4B, left panel). Also, the O-man-
nosylated glycoprotein RPTPz ([25, 30]; see also below) could be co-localizedwith the mono-
O-mannosyl glycan staining in the Purkinje cell layer (Fig 4B, middle panel) and in the cerebral
cortex (Fig 4B, right panel).
Mono-O-mannosyl glycans are localized to perineural nets
Glycoproteomic analysis identified the perineural net (PNN) proteins neurocan and versican
to be O-mannosylated ([28]; see also below). In the cerebellum, co-localizationwith neurocan
overlapped perfectly in the granular cell layer, whilst the Purkinje cell layer was not marked by
neurocan antibodies (Fig 5A). On sequential sections, versican distribution was highly compa-
rable to the α-O-Man antibody signal (Fig 5B). To further address the presence of mono-O-
mannosyl glycans in the PNN, we performed co-staining of the new α-O-Man antibody and
Fig 3. Mono-O-mannosyl glycan staining is pronounced in inhibitory neurons. Single channel images and merged channels including
counterstained nuclei by DAPI (sagittal sections) are shown. A) Co-staining of gephyrin, an inhibitory synapse protein of GABAergic neurons and the α-
O-Man antibody on WT murine brain cryosections of the hippocampus (first row) and cerebellum (second row). B) Staining of cryosections from GADCre
mice, expressing the cre protein specifically in GABAergic neurons. Cre-labeled GABAergic neurons were positive for α-O-Man antibody staining in the
hippocampus (third row) and cerebellum (fourth row). Inlay pictures in A and B, as well as C and D show higher magnification pictures. Asterisks indicate
the Purkinje cell layer. C) Peanut agglutinin (PNA), a marker for myelinated axons, did not co-localize with the signal of the α-O-Man antibody in the
hippocampus (first row) or the cerebellum (second row). D) Glial marker glial fibrillary acidic protein (GFAP) did not overlap with staining of the α-O-Man
antibody. Scale bars = 50 μm.
doi:10.1371/journal.pone.0166119.g003
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Wisteria floribunda agglutinin (WFA), a frequently usedmarker of the PNN [38]. We detected
a significant overlap of the staining, especially in the cerebral cortex (Fig 5C). In many cases,
WFA staining enclosedmono-O-mannosyl glycan staining, suggesting that O-mannosylated
proteins are more abundant close to cell bodies (Fig 5C, inlay).
Identification of mono-O-mannosylated proteins from the murine brain
by a glycoproteomics approach
Although O-mannosyl glycans are abundant, so far only few of the target proteins have been
identified frommammalian brain. To explore the portfolio of mono-O-mannosylated proteins,
we used previously established strategies for the detection of O-mannosylated peptides [31,
32]. The herein applied workflow is summarized in Fig 6. Briefly, proteins were extracted from
brains of 8–12 weeks old mice as detailed in Materials and Methods. After digestion with tryp-
sin, peptides/glycopeptideswere treated with PNGase F to remove N-linked glycans. Glycopep-
tides bearingO-linkedmannoses were then extracted by the mannose-binding lectin ConA
using LWAC following the previously describedprotocol of Vester-Christensen and coworkers
[31]. O-mannosylated peptides were identified by higher-energy collision-induceddissociation
(HCD)-basedmass spectrometry leading to informative peptide fragments due to a complete
loss of the glycan moieties from the precursor ion masses, either with or without the combina-
tion of α-mannosidase treatment, and liquid chromatography (LC)-MS after differential
Fig 4. Known O-mannosylated proteins are located to the cell types identified by the α-O-Man antibody. A)
α-DG as indicated by the IIH6 antibody reactive to matriglycan, and its interacting partner laminin preferentially
stained vasculature (arrowhead) and the glia limitans. Purkinje cell layer (asterisks) and granular cell layer
(bracket) were stained by the anti-laminin, the IIH6 and α-O-Man antibodies. IIH6 staining was performed following
the protocol of Beedle et al. 2012 to detect mouse antigens on mouse tissue [33]. B) Plexin-B2 (Plxnb2) and
RPTPζ showed comparable signal distribution as the α-O-Man antibody. Plxnb2 signals were located exclusively
to the Purkinje cell layer (asterisks), whereas RPTPζwas primarily located to the granular cell layer in the
cerebellum (abbreviated by C). In the cerebral cortex (CC), RPTPζ labeled single cells all of which were also
stained for by the α-O-Man antibody. Nuclei were stained by DAPI, sagittal cryosections of WT mouse brains were
used. Scale bars = 50 μm.
doi:10.1371/journal.pone.0166119.g004
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Fig 5. Mono-O-mannosyl glycans are concentrated in perineural nets. Sagittal cryosections were
counterstained with DAPI and stained with the indicated antibody or lectin. A) Perineural net protein neurocan
(Ncan) overlapped with the α-O-Man antibody signal in granular cell layer in the cerebellum (see merge), but was
absent from Purkinje cell layer (asterisk; see also single channel images). B) Cerebellar distribution of versican
(Vcan) was comparable to that of the α-O-Man antibody. Vcan staining was primarily detected in the granular cell
layer (bracket) and Purkinje cell layer (asterisk). C) Neurons positive for the α-O-Man antibody were often
surrounded by glycans reactive to WFA, a marker for perineural nets (PNNs), in the cerebral cortex (CC). Scale
bar = 50 μm and for inlay 25 μm.
doi:10.1371/journal.pone.0166119.g005
Fig 6. Schematic workflow for the enrichment of peptides bearing O-linked mannose. For the detailed protocol please refer to
the Materials and Methods section. In brief, murine brains were extracted and pulverized before protein extraction. Protein
suspensions were digested with trypsin and N-glycans removed by PNGase F treatment. Tryptic peptides were thereafter subjected
to ConA LWAC to enrich for mono-O-mannosylated peptides. Elution fractions were either analyzed directly (a), or after dimethyl
labeling (medium (M), light (L)) and α-mannosidase treatment (b) by LC-MS/MS and HCD fragmentation according to previously
described protocols [31].
doi:10.1371/journal.pone.0166119.g006
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tagging using stable isotopes. For the latter approach, samples were divided into two parts and
peptides labeled with either normal or deuterated formaldehyde. In one of the samples O-
linkedmannoses were clipped off with α-mannosidase. After inactivation of the enzyme, de-
mannosylated and mock treated peptides were combined and analyzed by LC-MS.We suc-
ceeded to unambiguously identify a total of 16 glycoproteins that are summarized in Table 1
(see also S6 Fig). LC-MS analysis of α-mannosidase treatment was obtained for a fraction of
these peptides (shown in Table 1 (bold letters), Fig 7 and S7 Fig). For RPTPz, we identified a
total of six new glycopeptides (Table 1, Fig 8 and S8 Fig). Further, nine of the identified glyco-
proteins are members of the cadherin superfamily of cell-adhesion proteins, including the type
II cadherin CDH11, the glycosylphosphatidylinisotol (GPI)-anchored CDH13 and seven pro-
tocadherins (Pcdhs). Amongst those, for Fat3, Pcdhgb5 and Pcdhga12 O-mannosylation is
described for the first time.We found two members of the plexin family (Plxna1 and Plxnb2),
and the ER-localized protein disulfide isomerase Pdia3, which, like cadherins, have been
described to be O-mannosylated previously in a “SimpleCell” system [31], and the PNN pro-
tein neurocan. In addition, mono-O-mannosyl glycans were identified for the first time on
neurexin 3 (Nrxn3), a known interactor of α-DG [46], and on inter-alpha-trypsin inhibitor
heavy chain family member 5 (Itih5), a modulator of the extracellularmatrix [47].
Table 1. Mono-O-mannosylated glycoproteins from murine brain.
UniProt Gene name Published Sequence Nr. of hexoses PEP Score Δ Score
P55288 Cdh11 [1] DMGGHMGGLSGTTK 2 4.4E-07 64.5 54.8
Q9WTR5 Cdh13 [1] EGPYIGHVMEGSPTGTTVMR 1 4.5E-155 156.8 138.5
Q9QXA3 Fat1 [1] EDVPTGSSVMTVSAHDEDTGR 2 1.9E-36 100.2 87.3
Q8BNA6 Fat3 VTDQGSPPMSATAIVR 2 7.7E-04 46.4 37.8
Q8BJD1 Itih5 QPEPDLKKTYDPR 1 1.5E-03 48.6 27.0
P55066 Ncan [2] AQGMPTLTSTSSEGHPEPK 2 2.0E-03 41.5 36.2
Q6P9K9 Nrxn3 NVPTANPTEPGIR 1 1.2E-03 58.8 47.9
E9PXQ7 Pcdh10 [1] TGTALLTIR 2 3.4E-19 100.0 65.1
F8VPK8 Pcdh9 [1] YSTVGVITVTDEDAGENK 2 2.6E-12 76.9 68.9
Q91Y09 Pcdhac2 [1] LNASDPDEGSNGELR 2 5.2E-10 87.7 76.1
Q91XY7 Pcdhga12 GASIASVTAHDPDSDK 2 9.1E-21 85.4 70.0
Q91XX5 Pcdhgb5 LPENVPPGTTVLR 1 2.4E-03 68.5 48.8
P27773 Pdia3 [1] YGVSGYPTLK 1 6.1E-08 88.0 73.3
P70206 Plxna1 [1] LTITGENLGLR 1 1.5E-03 50.9 28.3
B2RXS4 Plxnb2 [1] QGPQAGGTTLTINGTHLDTGSK 1 2.7E-09 62.8 48.6
B9EKR1 Ptprz1 [3] EPQVSTTTHYNHMGTK 1 3.1E-11 66.2 53.4
B9EKR1 Ptprz1 [3] TSMVSQIESPR 3 1.2E-10 89.5 74.7
B9EKR1 Ptprz1 [3] SDVPNTSPNSTSQHVAEFETER 1 3.0E-05 40.6 34.3
B9EKR1 Ptprz1 [3] HLHTVSQTLPQVTSAAER 4 8.1E-05 46.9 35.2
B9EKR1 Ptprz1 [3] MSSFSDMAYPSK 1 4.1E-04 70.2 56.6




In bold: Mono-O-mannosylated peptides validated by α-Mannosidase treatment [32].
Underlined: Corresponding peptides identified in the referred publications.
Extracted proteins were digested, O-mannosylated peptides enriched by ConA-lectin chromatography, and identified by LC-MS/MS. The quality of peptide
identification is indicated by PEP, Score, and Δ Score calculated by MaxQuant [36]. The UniProt accession numbers of all database entries containing the
identified peptide sequence are listed.
doi:10.1371/journal.pone.0166119.t001
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Discussion
Since the discovery of O-mannosyl glycans associated to rat proteoglycans [48], considerable
efforts have beenmade to characterize O-mannosyl glycan structures and to understand their
functions. An early study of Chai and co-workers showed that 30% of the total O-linked gly-
cans released from rabbit brain extracts belong to the O-mannosidic type [21]. Today, in the
mouse brain a wide variety of O-mannosyl glycan structures is known, including linear core
M1 and branched core M2 glycans, the core M3 matriglycan and also unsubstituted O-linked
mannoses [5, 24]. To investigate the distribution of O-mannosyl glycans in vivo, we established
a monoclonal antibody which, to the best of our current knowledge, specifically detects mono-
O-mannosyl glycans on cryosections from the murine brain.
The monoclonal antibody α-O-Man binds to O-mannosylated proteins onWestern Blots
(Fig 1A). That these proteins bear not only elongated O-mannosyl residues but also unsubsti-
tuted O-linkedmannoses was shown by the work of Breloy and coworkers who identified per-
methylated mannitol when analyzing glycan structures present on α-DG variants [34]. On
glycopeptide arrays α-O-Man binds highly specifically to an O-mannose peptide derived from
the POMT substrate protein KIAA1549 [31] and two peptides from α-DG [49], although to a
lower extent when compared with the original antigen (S1 Fig, #17–19, 26). Two of the tested
O-mannose peptides (S1 Fig, #20 and 21) as well as peptides with two adjacent threonine-
linkedO-mannose residues were not recognized (S1 Fig, #22–24). The new antibody showed
high selectivity towards mono-O-mannosylated peptides when compared to the same peptides
bearing linear Galß1,4GlcNAcß1,2Man and GlcNAcß1,2Man O-mannosyl glycans coupled to
threonine (S1 Fig). Furthermore, when presented as neoglycolipid, serine- as well as threonine-
linked α1-mannose was detected by α-O-Man (S2 Fig). In combination, these data suggest that
the newmonoclonal antibody α-O-Man prefers a specific glycopeptide conformation for rec-
ognition. In addition, underlying hydrophobic effects from the peptide backbonemight further
support the antibody glycan recognition.
Among the almost 500 different glycan structures tested on the NGL-based oligosaccharide
microarrays serine- and threonine-linkedα1-O-mannose probes were recognizedby α-
O-Man. The cross-reactivities of other mannose-related probes observed in the screening anal-
ysis are unlikely to be physiologically significant, as the probes that showed binding intensities
similar to those for the serine- and threonine-linkedα1-O-mannose probes, e.g. short α-linked
mannose sequences and β1-4-linked oligomannose glycans, are not represented on murine
brain glycoproteins to our knowledge.Moreover, the monoclonal α-O-Man did not target
Man3GlcNAc2, when presented in a peptide surrounding (S4 Fig). Hybrid or complex N-gly-
cans were not recognized at all (S2 Fig). Thus, it is highly unlikely, that minor interactions with
N-glycans impact on the immunofluorescence analyses presented. This is further supported by
the fact that PNGase F treatment of cryosections revealed unaltered distribution and intensity
of α-O-Man staining, whereas the primarily N-glycan dependentWFA-staining [39, 40] was
almost completely lost after N-glycan removal (Fig 1C). Moreover, the α-O-Man immunos-
taining of the murine brain is highly dependent on functional protein O-mannosylation, as
demonstrated by the absence of cell surface staining upon O-mannosylation inhibition in
Madin-Darby canine kidney cells (S5B Fig) and the strong reduction in signal intensity in
POMT2f/f;Emx1-Cre+mouse cerebral cortex (Fig 2B). The weak residual α-O-Man signal
obtained in the latter mice is most likely due to the conditional knockout strategy not targeting
all of the neuronal cells. Importantly, the pre-absorption of the α-O-Man antibody with the O-
mannosylated peptide obliterated the neural tissue immunostaining (S5A Fig). In addition,
expression of the POMT2 mannosyltransferase (revealed by POMT2-directed polyclonal anti-
body staining) is high in cells with abundant α-O-Man immunostaining, such as the Purkinje
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cell layer in the cerebellum, and the cornu ammonis in the hippocampus (S9 Fig) further sup-
porting the significance of our findings.
We found that mono-O-mannosyl glycans are prevalent in inhibitory GABAergic neurons,
such as the Purkinje cells in the cerebellum, as demonstrated by gephyrin co-staining and co-
localizationwith the cre protein expressed under the control of a GABAergic neuron-specific
promoter (Figs 2 and 3). Various knownO-mannosylated proteins localize to the GABAergic
Fig 7. Validation of O-mannosylation on RPTPζ. Samples were dimethyl labeled in the light and medium form, respectively.
After treating the light sample with α-mannosidase, both samples were mixed and analyzed by LC-MS/MS. Shown are four
extracted ion chromatograms of the m/z values of light and medium labeled peptide LLLPSTATSK in (A) the deglycosylated
form (543.8 amu and 547.9 amu) and in (B) the mannosylated form (624.9 amu and 628.9 amu, respectively). The glycopeptide
was detected only in the untreated sample (medium labeled), whereas the deglycosylated peptide (light labeled) was only
observed after mannosidase treatment. (C) HCD fragment spectrum of precursor mass 543.8 amu and (D) 628.9 amu
confirmed the sequence of the deglycosylated and O-mannosylated peptide LLLPSTATSK of RPTPζ.
doi:10.1371/journal.pone.0166119.g007
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Purkinje cell layer (Fig 4), such as α-DG and RPTPz [50], or are involved in Purkinje cell place-
ment like Plxnb2 [51]. The dystrophin-associated glycoprotein complex component α-DG and
α-DGO-mannosylation have been demonstrated to be not only important for neuroblast for-
mation and axon guidance during development of the nervous system, but also affect synaptic
plasticity at GABAergic synapses in the adult brain [52–54]. RPTPz was identified in this study
to be subject to substantial modification by mono-O-mannoses (Table 1, Figs 7 and 8 and S8
Fig). RPTPz contributes to a diverse array of biological processes required for normal develop-
ment and brain function, including regulation of the formation of Purkinje cell dendrites [50]
and aberrant glycosylation of RPTPz has been observed in a MEBmouse model lacking func-
tional POMGnT1 [30]. So far, only branching of O-mannosyl glycans by GnT-Vb was investi-
gated in respect to the function of O-mannosyl glycans on RPTPz [25]. Therein, the authors
showed that GnT-Vb promoted RPTPz dimer formation, leading to an inhibition of intrinsic
phosphatase activity. It will be a future challenge to investigate the functional role of unsubsti-
tuted O-mannosyl glycans on RPTPz.
Mono-O-mannosyl glycans were further localized in the PNN which provides structural
stability of the brain tissue (Fig 5). Mono-O-mannosyl glycan staining significantly overlaps
with that of the lecticans (e.g., versican and neurocan, Fig 5A and 5B) which interact with hya-
luronan and other extracellularmatrix proteins to form the PNN [55]. Our glycoproteomics
analysis further demonstrated mono-O-mannosylation of neurocan (Table 1, S6 Fig). These
findings are in good agreement with recent biochemical data that showed O-mannosylation of
neurocan and versican in high molecular weight protein extracts from bovine and mouse brain
[27, 28]. In these studies, O-glycans released from lectican-positive fractions, were analyzed by
MALDI-MS/MS and proteins were identified by LC-ESI-MS/MS.
Glycoproteomics revealedmono-O-mannosyl glycans on neurexin-3,marking the first inter-
actor of α-DG to carryO-mannosylation, and inter-alpha-trypsin inhibitor heavy chain family
member 5 (Itih5), being yet another protein involved in the upkeep and remodeling of the extra-
cellular matrix. The main carriers of mono-O-mannosyl glycans identified herein belong to the
Fig 8. Localization of O-mannosylated peptides of human RPTPζ. Schematic model of RPTPζ, illustrating the annotated
domains. Plasma membrane (PM) is indicated as a lipid bilayer. Positions of peptides containing extended O-mannosyl glycans
(indicated by green circles and -R) and O-linked N-Acetylgalactosamine mucin-type glycans (yellow squares) found by Trinidad and
coworkers are shown [29]. The position of O-hexosylated peptides identified in this study is indicated as a green circle with a
horizontal black bar.
doi:10.1371/journal.pone.0166119.g008
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cadherin and plexin family, yielding 7 and 2 members, respectively (Table 1, S6 and S7 Figs). O-
mannosylation of numerous members of these protein families has been recently demonstrated
in simplified human breast cancer cells [31], but, with the exception of CDH13, not yet from
native tissues. Further, for Fat3, Pcdhgb5 and Pcdhga12 O-mannosylation is described for the
first time. The fact that the largest portion of proteins identified are cadherin and plexin family
members, demonstrates mono-O-mannosylation of these families in vivo.
Moreover, we identifiedmono-O-mannosyl glycans on the ER-localized protein disulfide
isomerase Pdia3 (Table 1, S6 and S7 Figs). PDIs transfer oxidizing equivalents to newly synthe-
sized polypeptides, leading to the formation or rearrangement of protein disulfide bonds.
Thereby they fulfill a crucial role for oxidative protein folding in the ER which is an essential
function of eukaryotic cells (reviewed in [56]). The mannosylated peptide identified in mouse
Pdia3, includes a conservedProThr-motif that has been demonstrated to carry an O-linked
mannose in PDIA3 from human breast cancer cells [31] (S10 Fig). Most interestingly, we very
recently found O-mannosyl glycans also in the ER-luminal PDIs and PDI-like proteins from
baker´s yeast and found that modification by O-mannosylation occurred in a conserved resi-
due in the proximity of the catalytic CysXXCys motifs [57].
The combination of in situ staining and glycoproteomics illustrates that mono-O-mannosy-
lation is abundant in the mammalian brain and targets many glycoproteins. Numerous of
these proteins are possible contributors to the neurological abnormalities observed inWWS
and other α-dystroglycanopathy patients. However, it will be a challenge to address this issue
since in animal models that lack O-mannosylation the concomitant aberrant glycosylation of
α-DG drives highly dominant neurological phenotypes.
Supporting Information
S1 Fig. The monoclonalα-O-Man antibody specificallyrecognizesunsubstituted O-man-
nose linked to threonine in a diverse peptide context.Microarray analysis elucidating the
monoclonal antibody RKU-1-3-5 antibody recognition of O-mannosyl peptides 7–31 at differ-
ent antibody concentrations. Strong recognition of antigen peptide 26 and weak recognition of
O-mannosyl peptides 17–19 were observed. Fluorescence read-out after incubation with a bio-
tin labeled secondary anti-rabbit IgG antibody and streptavidin Cy5. The diagram shows mean
values and standard deviations of 5 spot replicates per peptide. Peptide backbones were the
same for peptides no. 8, 17, 28 (PVPGKPTVTIR),no. 9, 18, 29 (RGAIIQTPTLG), no. 30, 31
(GTG), no. 7, 10, 25 (YATAVA), no. 11, 19 (SQSLEETISPR), no. 12, 20 (SGPLDGGTLLTIR),
no. 13, 14, 21, 22 (NAPSGTTVIHLNA), no. 15, 23 (QGPQAGGTTLTIHG), no. 16, 24
(EPGGSYITTVSATD) and no. 26, 27 (YATAV). Green circles, blue squares and yellow circle
represent mannose, N-Acetylglucosamine and galactose, respectively. Linkage conformations
are indicated. For a comprehensive summary of the peptides used in this array and their pro-
tein origin please refer to S3 Table.
(TIF)
S2 Fig. The α-O-Man antibody recognizes serine- and threonine-linkedmannoses among
themammalian type glycan sequences.A) The 492 lipid-linked probes are arranged accord-
ing to their backbone sequences as annotated in the coloured panels below the Fig Lac, lactose;
LacNAc, N-acetyllactosamine; LNnT, lacto-N-neotetraose; LNT, lacto-N-tetraose; PolyLac,
polylactosamine;GAGs, glycosaminoglycans;Misc., miscellaneous. The signals are means of
fluorescence intensities of duplicate spots, printed at 5 fmol with error bars representing half of
the difference between the two values. X denotes signal with large error bar (no significant
binding). The signals shown together with the probe sequences are in S3 File. In separate exper-
iments (not shown) binding signals were not detectedwhen using the detection antibody,
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biotinylated anti-rabbit IgG. B) Structures of O-mannosyl serine or threonine related probes
investigated in the microarray. DHPE, 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine;
Succ, succinic anhydride linker.
(TIF)
S3 Fig. Results for 15 probes selected from ‘N-glycan related Array Set 1’ at different dilu-
tions of RKU-1-3-5 antibody. Probes of oligo- and high-mannose type N-glycans and O-man-
nosyl serine and threonine probes are shown here. The complete list of probes in the array,
their sequences and binding scores are provided in supplemental S2 Table.
(TIF)
S4 Fig. The N-glycan structureMan3GlcNAc2 is not identified by α-O-Man in a varying
peptide context.Microarray analysis elucidating a) the mAb RKU1-3-5 antibody recognition
of the pentasaccharide core Man3GlcNAc2 N-glycopeptides 38–41, no recognition; b) positive
control, Biotin-ConA, recognition of all pentasaccharide core glycopeptides. Fluorescence
read-out: a) incubation with a biotin labeled secondary anti-rabbit IgG antibody and then
streptavidin Cy5; b) incubation with streptavidin Cy5. The diagrams shows mean values and
standard deviations of 5 spot replicates per peptide. Peptide sequences are: no. 38
VVNSTTGPGEHLR, no. 39WVSNKTEGR, no. 40NLTALPPDLPK and no. 41
LQNLTLPTNASIK (an asterisk marks the site of the pentasaccharide). Green circles and blue
squares represent mannose and N-Acetylglucosamine, respectively. Linkage conformations are
indicated. For further information on the used peptides see S4 Table.
(TIF)
S5 Fig. Preadsorption studies of α-O-Man antibody and comparison of α-O-Man antibody
reactivity on Madin-Darby canine kidney cells.A) Pre-adsorption with an O-mannosylated
peptide completely abrogated signal pattern obtained by the α-O-Man antibody on wild-type
(WT) murine cerebellar cryosections (right panel), whereas pre-adsorption with the corre-
sponding peptide lacking the O-linkedmannose did not influence the staining. Nuclei were
counterstained with DAPI, sections were cut sagittally. B) Madin-Darby canine kidney cells
were grown in the presence or absence of O-mannosylation inhibitor R3A-5a [8] for three
days. Fixed cells were stained with a monoclonal antibody (this study; α-O-Man) or a previ-
ously describedpolyclonal antibody (T[α-1Man]; [8]), both of which were raised against a pep-
tide harboring an α-1-mannosylated threonine residue. Inhibitor-treatment completely
abolished staining of cell-contact sites. Cellular nuclei are counterstained with DAPI. C) Co-
localization of α-DG using α-IIH6 and α-O-Man on sequential sections showed substantial
overlap, for example in the Purkinje cell layer (asterisk), whereas vasculature (arrowhead) was
not labeled by α-O-Man antibody. Scale bar = 50 μm (A/C),10 μm (B).
(TIF)
S6 Fig. Peptide spectra fromHCD analysis.Glycopeptides identified in HCD-MS/MS analy-
sis. Individual HCD fragment spectra/patterns of all identified glycopeptides are given. y-frag-
ments are colored red and b-fragments are colored blue. Peptide sequence and the
corresponding fragment patterns are depicted below each spectrum.Deamidation at aspara-
gine is indicated by “de”. Presence of glycosylation was determined by neutral loss of hexoses
from the precursor ion mass. Localization of glycosylation can be ambiguously mapped to ser-
ine and threonine residues. Position of hexose indicator “he” is based on the suggestion by
MaxQuant.
(PDF)
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S7 Fig. Validation of O-mannosylationof selectedpeptides. Samples were dimethyl labeled
in the light and medium form, respectively. After treating the light sample with α-mannosidase
both samples were mixed and analyzed by LC-MS/MS. Shown are four extracted ion chro-
matograms of the m/z values of light and medium labeled peptides for CDH11 (A), deaminated
PCDHAC2 (B), PDIA3 (C) and PCDH9 (D). Inlay picture 1 always shows the respective degly-
cosylated, whereas inlay picture 2 refers to the mannosylated form. The glycopeptide was
detected only in the untreated sample (medium labeled), whereas the deglycosylated peptide
(light labeled) was only observed after mannosidase treatment. Inlay picture 3 shows HCD
fragment spectrumof the respective precursor mass and inlay picture 4 confirms the sequence
of the deglycosylated and O-mannosylated peptide of the respective protein.
(PDF)
S8 Fig. Localizationof O-mannosylatedpeptides in human RPTPz.Amino acid sequence of
the extracellular domain of human RPTPz. O-hexosylated peptides identified in this study are
given in bold red, whereas peptides previously identified by Trinidad and coworkers are
highlighted in bold green [29].
(TIF)
S9 Fig. Distribution of POMT2 inWTmurine brain cryosections.Sagittal cryosectionsof
WTmurine brain were stained with the previously describedα-POMT2 antibody (see S1 File).
As a control, POMT2 antibodies were preadsorbed to nitrocellulose-boundrecombinant epi-
tope and the resulting supernatant was used for immunodetection (pread α-POMT2; for details
see S1 File section). POMT2 signal distribution was comparable to α-O-Man immunostaining
(compare to Fig 2) and completely absent after preadsorption. Nuclei were counterstained with
DAPI. Scale bar = 50 μm.
(TIF)
S10 Fig. Conservationof amino acids in protein disulfide-isomerase A3 (PDIA3). Align-
ment of sequences for PDIA3 protein or respective homologues from different species includ-
ing, from top to bottom, Saccharomyces cerevisiae, Caenorhabditis elegans, Xenopus laevis,
Danio rerio, Gallus gallus, Rattus norvegicus, Bos taurus,Mus musculus andHomo sapiens. The
sequence is an extract from both Thioredoxin domains. Similarity is indicated by “.”, high simi-
larity by “:” and identical amino acids by” ”. Identified glycopeptides frommouse brain (this
study) and human breast cancer cells [31] are depicted in bold green letters. Bold red letters
indicate O-mannosylated serine or threonine residues.
(TIF)
S11 Fig. Synthesis outline for the glycopeptidesused in this study. A) An overviewof the
Fmoc-Solid-phase peptide synthesis of the O-mannosyl glycopeptides. B) An overviewof the





S2 File. HPLC chromatograms of synthesizedglycopeptidesused in the peptide glycoar-
rays.
(DOCX)
S3 File. Data file of NGL-basedmicroarray screening analysis: List of 492 probes included
in the NGL-basedmicroarray screening analysis, their sequences and the fluorescence
Mono-O-Mannosylation and Mammalian Brain
PLOS ONE | DOI:10.1371/journal.pone.0166119 November 3, 2016 19 / 23
intensities at 5 fmol per probe spot of binding withmonoclonal antibody RKU-1-3-5.
(XLSX)
S1 Table. Antibody and lectins used in this study. Monoclonal or polyclonal antibodies are
indicated with m or p, respectively. Vendors and order numbers are provided, Antibody IDs
from the Antibody Registry are indicated when available and used dilutions are given.
(DOCX)
S2 Table. Tabulation of 52 probes included in N-glycan related Array Set 1 and their bind-
ing scores (fluorescence intensities at 5 fmol per probe spot) at different RKU-1-3-5 anti-
body dilutions.
(DOCX)
S3 Table. Synthetic O-mannosyl peptides used in the antibodymicroarray analysis.Glycan
positions are indicated in the peptide sequence by an asterisk (). Spacers are indicated in the
peptide sequence (Sp).
(DOCX)
S4 Table. Synthetic N-glycopeptidesused in themAb RKU-1-3-5 antibodymicroarray anal-
ysis.Glycan positions are indicated in the peptide sequence by an asterisk (). Spacers are indi-
cated in the peptide sequence (Sp).
(DOCX)
Acknowledgments
We are very grateful to A. Metschies, G. Günther and F. Genovese for excellent technical assis-
tance.We thank Dr. Hannah Monyer and Dr. Anne Herb for providing the GADCre mice. This
work was supported by the Deutsche Forschungsgemeinschaft, Sonderforschungsbereich1036,
project 11 (to S.S.). S.S. is a member of the excellence cluster CellNetworks. Financial support by
theMinisterium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen,
the Senatsverwaltung fürWirtschaft, Technologie und Forschung des Landes Berlin, and the
Bundesministerium für Bildung und Forschung is gratefully acknowledged (to U.W.). Supported
byWellcome Trust Grants WT093378MA,WT099197MA and 108430/Z/15/Z (to T.F.).
Author Contributions
Funding acquisition:UWTF SS.
Investigation:MFB PRW JY YL TF UW TR SS.
Resources: FMHH.
Supervision:ML FM TF UW SS.
Validation: FM TF UW SS.
Writing – original draft:MFB PRW ML FM TR SS.
Writing – review& editing:MFB PRW YL TF UWTR SS.
References
1. Lommel M, Strahl S. Protein O-mannosylation: conserved from bacteria to humans. Glycobiology.
2009; 19(8):816–28. Epub 2009/05/12. doi: cwp066 [pii] doi: 10.1093/glycob/cwp066 PMID:
19429925.
Mono-O-Mannosylation and Mammalian Brain
PLOS ONE | DOI:10.1371/journal.pone.0166119 November 3, 2016 20 / 23
2. Loibl M, Strahl S. Protein O-mannosylation: what we have learned from baker’s yeast. Biochim Bio-
phys Acta. 2013; 1833(11):2438–46. doi: 10.1016/j.bbamcr.2013.02.008 PMID: 23434682.
3. Manya H, Chiba A, Yoshida A, Wang X, Chiba Y, Jigami Y, et al. Demonstration of mammalian protein
O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity.
Proc Natl Acad Sci U S A. 2004; 101(2):500–5. Epub 2003/12/31. doi: 10.1073/pnas.0307228101
0307228101 [pii]. PMID: 14699049; PubMed Central PMCID: PMC327176.
4. Kogelberg H, Chai W, Feizi T, Lawson AM. NMR studies of mannitol-terminating oligosaccharides
derived by reductive alkaline hydrolysis from brain glycoproteins. Carbohydr Res. 2001; 331(4):393–
401. PMID: 11398981.
5. Praissman JL, Wells L. Mammalian O-mannosylation pathway: glycan structures, enzymes, and pro-
tein substrates. Biochemistry. 2014; 53(19):3066–78. doi: 10.1021/bi500153y PMID: 24786756;
PubMed Central PMCID: PMC4033628.
6. Yoshida-Moriguchi T, Campbell KP. Matriglycan: a novel polysaccharide that links dystroglycan to the
basement membrane. Glycobiology. 2015; 25(7):702–13. doi: 10.1093/glycob/cwv021 PMID:
25882296; PubMed Central PMCID: PMCPMC4453867.
7. Willer T, Prados B, Falcon-Perez JM, Renner-Muller I, Przemeck GK, Lommel M, et al. Targeted dis-
ruption of the Walker-Warburg syndrome gene Pomt1 in mouse results in embryonic lethality. Proc
Natl Acad Sci U S A. 2004; 101(39):14126–31. PMID: 15383666. doi: 10.1073/pnas.0405899101
8. Lommel M, Winterhalter PR, Willer T, Dahlhoff M, Schneider MR, Bartels MF, et al. Protein O-manno-
sylation is crucial for E-cadherin-mediated cell adhesion. Proc Natl Acad Sci U S A. 2013; 110
(52):21024–9. Epub 2013/12/04. doi: 10.1073/pnas.1316753110 1316753110 [pii]. PMID: 24297939;
PubMed Central PMCID: PMC3876218.
9. Bonnemann CG, Wang CH, Quijano-Roy S, Deconinck N, Bertini E, Ferreiro A, et al. Diagnostic
approach to the congenital muscular dystrophies. Neuromuscul Disord. 2014; 24(4):289–311. doi: 10.
1016/j.nmd.2013.12.011 PMID: 24581957.
10. Barresi R, Campbell KP. Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell
Sci. 2006; 119(Pt 2):199–207. PMID: 16410545. doi: 10.1242/jcs.02814
11. Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, et al. Post-translational disruption of
dystroglycan-ligand interactions in congenital muscular dystrophies. Nature. 2002; 418(6896):417–22.
Epub 2002/07/26. doi: 10.1038/nature00837 nature00837 [pii]. PMID: 12140558.
12. Beltran-Valero de Bernabe D, Currier S, Steinbrecher A, Celli J, van Beusekom E, van der Zwaag B,
et al. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration
disorder Walker-Warburg syndrome. Am J Hum Genet. 2002; 71(5):1033–43. PMID: 12369018. doi:
10.1086/342975
13. Judas M, Sedmak G, Rados M, Sarnavka V, Fumic K, Willer T, et al. POMT1-associated walker-war-
burg syndrome: a disorder of dendritic development of neocortical neurons. Neuropediatrics. 2009; 40
(1):6–14. Epub 2009/07/30. doi: 10.1055/s-0029-1224099 PMID: 19639522.
14. Hu H, Yang Y, Eade A, Xiong Y, Qi Y. Breaches of the pial basement membrane and disappearance of
the glia limitans during development underlie the cortical lamination defect in the mouse model of mus-
cle-eye-brain disease. J Comp Neurol. 2007; 501(1):168–83. doi: 10.1002/cne.21238 PMID:
17206611.
15. Waite A, Brown SC, Blake DJ. The dystrophin-glycoprotein complex in brain development and dis-
ease. Trends Neurosci. 2012; 35(8):487–96. doi: 10.1016/j.tins.2012.04.004 PMID: 22626542.
16. Ervasti JM, Campbell KP. A role for the dystrophin-glycoprotein complex as a transmembrane linker
between laminin and actin. J Cell Biol. 1993; 122(4):809–23. Epub 1993/08/01. PMID: 8349731;
PubMed Central PMCID: PMC2119587.
17. Sugiyama J, Bowen DC, Hall ZW. Dystroglycan binds nerve and muscle agrin. Neuron. 1994; 13
(1):103–15. PMID: 8043271.
18. Goddeeris MM, Wu B, Venzke D, Yoshida-Moriguchi T, Saito F, Matsumura K, et al. LARGE glycans
on dystroglycan function as a tunable matrix scaffold to prevent dystrophy. Nature. 2013; 503
(7474):136–40. Epub 2013/10/18. doi: 10.1038/nature12605 nature12605 [pii]. PMID: 24132234;
PubMed Central PMCID: PMC3891507.
19. Liu J, Ball SL, Yang Y, Mei P, Zhang L, Shi H, et al. A genetic model for muscle-eye-brain disease in
mice lacking protein O-mannose 1,2-N-acetylglucosaminyltransferase (POMGnT1). Mech Dev. 2006;
123(3):228–40. PMID: 16458488. doi: 10.1016/j.mod.2005.12.003
20. Hu H, Li J, Gagen CS, Gray NW, Zhang Z, Qi Y, et al. Conditional knockout of protein O-mannosyl-
transferase 2 reveals tissue-specific roles of O-mannosyl glycosylation in brain development. J Comp
Neurol. 2011; 519(7):1320–37. Epub 2011/04/01. doi: 10.1002/cne.22572 PMID: 21452199.
Mono-O-Mannosylation and Mammalian Brain
PLOS ONE | DOI:10.1371/journal.pone.0166119 November 3, 2016 21 / 23
21. Chai W, Yuen CT, Kogelberg H, Carruthers RA, Margolis RU, Feizi T, et al. High prevalence of 2-
mono- and 2,6-di-substituted manol-terminating sequences among O-glycans released from brain gly-
copeptides by reductive alkaline hydrolysis. Eur J Biochem. 1999; 263(3):879–88. Epub 1999/09/01.
ejb572 [pii]. PMID: 10469154.
22. Yuen CT, Chai W, Loveless RW, Lawson AM, Margolis RU, Feizi T. Brain contains HNK-1 immunore-
active O-glycans of the sulfoglucuronyl lactosamine series that terminate in 2-linked or 2,6-linked hex-
ose (mannose). J Biol Chem. 1997; 272(14):8924–31. Epub 1997/04/04. PMID: 9083013.
23. Breloy I, Pacharra S, Aust C, Hanisch FG. A sensitive gel-based global O-glycomics approach reveals
high levels of mannosyl glycans in the high mass region of the mouse brain proteome. Biol Chem.
2012; 393(8):709–17. Epub 2012/09/05. doi: 10.1515/hsz-2012-0214 PMID: 22944674.
24. Stalnaker SH, Aoki K, Lim JM, Porterfield M, Liu M, Satz JS, et al. Glycomic analyses of mouse models
of congenital muscular dystrophy. J Biol Chem. 2011; 286(24):21180–90. Epub 2011/04/05. doi: 10.
1074/jbc.M110.203281 PMID: 21460210; PubMed Central PMCID: PMC3122180.
25. Abbott KL, Matthews RT, Pierce M. Receptor tyrosine phosphatase beta (RPTPbeta) activity and sig-
naling are attenuated by glycosylation and subsequent cell surface galectin-1 binding. J Biol Chem.
2008; 283(48):33026–35. Epub 2008/10/08. M803646200 [pii] doi: 10.1074/jbc.M803646200 PMID:
18838383; PubMed Central PMCID: PMC2586282.
26. Bleckmann C, Geyer H, Lieberoth A, Splittstoesser F, Liu Y, Feizi T, et al. O-glycosylation pattern of
CD24 from mouse brain. Biol Chem. 2009; 390(7):627–45. Epub 2009/03/17. doi: 10.1515/BC.2009.
044 PMID: 19284289.
27. Pacharra S, Hanisch FG, Breloy I. Neurofascin 186 is O-mannosylated within and outside of the mucin
domain. J Proteome Res. 2012; 11(8):3955–64. Epub 2012/07/04. doi: 10.1021/pr200996y PMID:
22746206.
28. Pacharra S, Hanisch FG, Muhlenhoff M, Faissner A, Rauch U, Breloy I. The lecticans of mammalian
brain perineural net are O-mannosylated. J Proteome Res. 2013; 12(4):1764–71. Epub 2013/02/23.
doi: 10.1021/pr3011028 PMID: 23428289.
29. Trinidad JC, Schoepfer R, Burlingame AL, Medzihradszky KF. N- and O-glycosylation in the murine
synaptosome. Molecular & cellular proteomics: MCP. 2013; 12(12):14. Epub 2013/07/03. doi: 10.
1074/mcp.M113.030007 PMID: 23816992.
30. Dwyer CA, Baker E, Hu H, Matthews RT. RPTPzeta/phosphacan is abnormally glycosylated in a
model of muscle-eye-brain disease lacking functional POMGnT1. Neuroscience. 2012; 220:47–61.
doi: 10.1016/j.neuroscience.2012.06.026 PMID: 22728091; PubMed Central PMCID: PMC3412926.
31. Vester-Christensen MB, Halim A, Joshi HJ, Steentoft C, Bennett EP, Levery SB, et al. Mining the O-
mannose glycoproteome reveals cadherins as major O-mannosylated glycoproteins. Proc Natl Acad
Sci U S A. 2013; 110(52):21018–23. doi: 10.1073/pnas.1313446110 PMID: 24101494; PubMed Cen-
tral PMCID: PMC3876253.
32. Winterhalter PR, Lommel M, Ruppert T, Strahl S. O-glycosylation of the non-canonical T-cadherin
from rabbit skeletal muscle by single mannose residues. FEBS Lett. 2013; 587(22):3715–21. doi: 10.
1016/j.febslet.2013.09.041 PMID: 24113656.
33. Beedle AM, Turner AJ, Saito Y, Lueck JD, Foltz SJ, Fortunato MJ, et al. Mouse fukutin deletion impairs
dystroglycan processing and recapitulates muscular dystrophy. J Clin Invest. 2012; 122(9):3330–42.
doi: 10.1172/JCI63004 PMID: 22922256; PubMed Central PMCID: PMCPMC3428090.
34. Breloy I, Schwientek T, Gries B, Razawi H, Macht M, Albers C, et al. Initiation of mammalian O-manno-
sylation in vivo is independent of a consensus sequence and controlled by peptide regions within and
upstream of the alpha-dystroglycan mucin domain. J Biol Chem. 2008; 283(27):18832–40. Epub 2008/
05/06. doi: 10.1074/jbc.M802834200 M802834200 [pii]. PMID: 18456664.
35. Sambrook J, Russel DW. Molecular cloning: a laboratory manual. 3rd ed: Cold Spring Harbor Labora-
tory Press, Cold Spring Harbor, NY; 2001.
36. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass
accuracies and proteome-wide protein quantification. Nat Biotech. 2008; 26(12):1367–72. doi: 10.
1038/nbt.1511 PMID: 19029910.
37. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M. Andromeda: a peptide search
engine integrated into the MaxQuant environment. J Proteome Res. 2011; 10(4):1794–805. doi: 10.
1021/pr101065j PMID: 21254760.
38. Hartig W, Brauer K, Bruckner G. Wisteria floribunda agglutinin-labelled nets surround parvalbumin-
containing neurons. Neuroreport. 1992; 3(10):869–72. PMID: 1421090.
39. Che MI, Huang J, Hung JS, Lin YC, Huang MJ, Lai HS, et al. beta1, 4-N-acetylgalactosaminyltransfer-
ase III modulates cancer stemness through EGFR signaling pathway in colon cancer cells. Oncotarget.
2014; 5(11):3673–84. doi: 10.18632/oncotarget.1981 PMID: 25003232; PubMed Central PMCID:
PMCPMC4116512.
Mono-O-Mannosylation and Mammalian Brain
PLOS ONE | DOI:10.1371/journal.pone.0166119 November 3, 2016 22 / 23
40. Cabrera PV, Pang M, Marshall JL, Kung R, Nelson SF, Stalnaker SH, et al. High throughput screening
for compounds that alter muscle cell glycosylation identifies new role for N-glycans in regulating sarco-
lemmal protein abundance and laminin binding. J Biol Chem. 2012; 287(27):22759–70. doi: 10.1074/
jbc.M111.334581 PMID: 22570487; PubMed Central PMCID: PMCPMC3391114.
41. Kim KK, Adelstein RS, Kawamoto S. Identification of neuronal nuclei (NeuN) as Fox-3, a new member
of the Fox-1 gene family of splicing factors. J Biol Chem. 2009; 284(45):31052–61. doi: 10.1074/jbc.
M109.052969 PMID: 19713214; PubMed Central PMCID: PMCPMC2781505.
42. Whitney ER, Kemper TL, Rosene DL, Bauman ML, Blatt GJ. Calbindin-D28k is a more reliable marker
of human Purkinje cells than standard Nissl stains: a stereological experiment. J Neurosci Methods.
2008; 168(1):42–7. doi: 10.1016/j.jneumeth.2007.09.009 PMID: 17961663.
43. Sassoe-Pognetto M, Frola E, Pregno G, Briatore F, Patrizi A. Understanding the molecular diversity of
GABAergic synapses. Front Cell Neurosci. 2011; 5:4. doi: 10.3389/fncel.2011.00004 PMID:
21713106; PubMed Central PMCID: PMCPMC3112311.
44. Tolu S, Avale ME, Nakatani H, Pons S, Parnaudeau S, Tronche F, et al. A versatile system for the neu-
ronal subtype specific expression of lentiviral vectors. FASEB J. 2010; 24(3):723–30. doi: 10.1096/fj.
09-139790 PMID: 19858094.
45. Perrot V, Vazquez-Prado J, Gutkind JS. Plexin B regulates Rho through the guanine nucleotide
exchange factors leukemia-associated Rho GEF (LARG) and PDZ-RhoGEF. J Biol Chem. 2002; 277
(45):43115–20. doi: 10.1074/jbc.M206005200 PMID: 12183458.
46. Sugita S, Saito F, Tang J, Satz J, Campbell K, Sudhof TC. A stoichiometric complex of neurexins and
dystroglycan in brain. J Cell Biol. 2001; 154(2):435–45. Epub 2001/07/27. PMID: 11470830; PubMed
Central PMCID: PMC2150755. doi: 10.1083/jcb.200105003
47. Himmelfarb M, Klopocki E, Grube S, Staub E, Klaman I, Hinzmann B, et al. ITIH5, a novel member of
the inter-alpha-trypsin inhibitor heavy chain family is downregulated in breast cancer. Cancer Lett.
2004; 204(1):69–77. PMID: 14744536.
48. Finne J, Krusius T, Margolis RK, Margolis RU. Novel mannitol-containing oligosaccharides obtained
by mild alkaline borohydride treatment of a chondroitin sulfate proteoglycan from brain. J Biol Chem.
1979; 254(20):10295–300. PMID: 39937.
49. Mo KF, Fang T, Stalnaker SH, Kirby PS, Liu M, Wells L, et al. Synthetic, structural, and biosynthetic
studies of an unusual phospho-glycopeptide derived from alpha-dystroglycan. J Am Chem Soc. 2011;
133(36):14418–30. doi: 10.1021/ja205473q PMID: 21812486; PubMed Central PMCID:
PMCPMC3176502.
50. Tanaka M, Maeda N, Noda M, Marunouchi T. A chondroitin sulfate proteoglycan PTPzeta /RPTPbeta
regulates the morphogenesis of Purkinje cell dendrites in the developing cerebellum. J Neurosci.
2003; 23(7):2804–14. PMID: 12684467.
51. Friedel RH, Kerjan G, Rayburn H, Schuller U, Sotelo C, Tessier-Lavigne M, et al. Plexin-B2 controls
the development of cerebellar granule cells. J Neurosci. 2007; 27(14):3921–32. doi: 10.1523/
JNEUROSCI.4710-06.2007 PMID: 17409257.
52. Wright KM, Lyon KA, Leung H, Leahy DJ, Ma L, Ginty DD. Dystroglycan organizes axon guidance cue
localization and axonal pathfinding. Neuron. 2012; 76(5):931–44. doi: 10.1016/j.neuron.2012.10.009
PMID: 23217742; PubMed Central PMCID: PMCPMC3526105.
53. Moore SA, Saito F, Chen J, Michele DE, Henry MD, Messing A, et al. Deletion of brain dystroglycan
recapitulates aspects of congenital muscular dystrophy. Nature. 2002; 418(6896):422–5. Epub 2002/
07/26. doi: 10.1038/nature00838 nature00838 [pii]. PMID: 12140559.
54. Pribiag H, Peng H, Shah WA, Stellwagen D, Carbonetto S. Dystroglycan mediates homeostatic synap-
tic plasticity at GABAergic synapses. Proc Natl Acad Sci U S A. 2014; 111(18):6810–5. doi: 10.1073/
pnas.1321774111 PMID: 24753587; PubMed Central PMCID: PMCPMC4020085.
55. Howell MD, Gottschall PE. Lectican proteoglycans, their cleaving metalloproteinases, and plasticity in
the central nervous system extracellular microenvironment. Neuroscience. 2012; 217:6–18. doi: 10.
1016/j.neuroscience.2012.05.034 PMID: 22626649; PubMed Central PMCID: PMCPMC3796366.
56. Wilkinson B, Gilbert HF. Protein disulfide isomerase. Biochim Biophys Acta. 2004; 1699(1–2):35–44.
doi: 10.1016/j.bbapap.2004.02.017 PMID: 15158710.
57. Neubert P, Halim A, Zauser M, Essig A, Joshi HJ, Zatorska E, et al. Mapping the O-mannose glycopro-
teome in Saccharomyces cerevisiae. Mol Cell Proteomics. 2016. doi: 10.1074/mcp.M115.057505
PMID: 26764011.
Mono-O-Mannosylation and Mammalian Brain
PLOS ONE | DOI:10.1371/journal.pone.0166119 November 3, 2016 23 / 23
